Naquotinib (mesylate)
Naquotinib (mesylate) Basic information
- Product Name:
- Naquotinib (mesylate)
- Synonyms:
-
- Naquotinib (mesylate)
- Naquotinib mesylate (ASP8273 mesylate)
- ASP8273 (mesylate)
- EGFR,ASP8273,ErbB-1,ASP 8273,Inhibitor,Naquotinib mesylate,ASP-8273,HER1,Epidermal growth factor receptor,inhibit,Naquotinib
- Naquotinib mesylate (ASP-8273)
- CAS:
- 1448237-05-5
- MF:
- C31H46N8O6S
- MW:
- 658.81194
- Mol File:
- 1448237-05-5.mol
Naquotinib (mesylate) Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO : 12.5 mg/mL (18.97 mM)
- form
- Solid
- color
- Light yellow to yellow
Naquotinib (mesylate) Usage And Synthesis
Uses
Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
in vivo
Oral Naquotinib treatment dose dependently induces tumor regression in NCI-H1975 (L858R/T790M), HCC827 (del ex19) and PC-9 (del ex19) xenograft models. Dosing schedules does not affect the efficacy of Naquotinib. In an NCI-H1975 xenograft model, complete regression of tumor is achieved after 14-days of Naquotinib treatment. Complete regression is maintained in 50% of mice more than 85 days after cessation of Naquotinib treatment[2].
IC 50
EGFRL858R/T790M; EGFRL858R; EGFRExon 19 deletion; EGFRExon 19 deletion/T790M; EGFR: 230 nM (IC50)
References
[1] Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445.AM2014-1728
[2] Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2586. doi:10.1158/1538-7445.AM2015-2586
Naquotinib (mesylate)Supplier
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- +86 13524779951; 13524779951
- 2075692521@qq.com
- Tel
- 571-89925085
- sales@amadischem.com
- Tel
- +1-800-259-7612
- info@musechem.com
Naquotinib (mesylate)(1448237-05-5)Related Product Information
- Asciminib
- CCT 244747
- 6-amino-1,3-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
- 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE
- HS-173
- BI-9564
- BenzaMide, 4-[[2-[3,5-bis(trifluoroMethyl)phenyl]-4,5-bis(4-Methoxyphenyl)-1H-iMidazol-1-yl]Methyl]-
- 4-Propylphenol